Stanley-Laman Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Stanley-Laman Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-61,353	Closed	-$5.78M	–	224
2018 Q2	$5.78M	Sell	61,353 -1,164	-2%	-$102K	1.3%	15
2018 Q1	$5.07M	Sell	62,517 -2,416	-4%	-$207K	1.15%	20
2017 Q4	$5.79M	Sell	64,933 -8,293	-11%	-$721K	1.25%	14
2017 Q3	$6.82M	Buy	+73,226	New	+$6.47M	1.82%	3

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stanley-Laman Group's BMRN Position: Q3 2018 in Review

Stanley-Laman Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2018, closing a stake of 61,353 shares — an estimated $5.78M sold.

Stanley-Laman Group first reported a position in BMRN in Q3 2017 and held it in 4 quarters. The position peaked at $6.82M in Q3 2017. 459 funds tracked by Wall St. Rank hold BMRN as of Q3 2018.

Stanley-Laman Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Stanley-Laman Group sold 61,353 BioMarin Pharmaceuticals shares in Q3 2018, an estimated $5.78M.
Stanley-Laman Group first reported a position in BioMarin Pharmaceuticals in Q3 2017 and held it in 4 quarters.
Stanley-Laman Group's BioMarin Pharmaceuticals position peaked at $6.82M in Q3 2017.
459 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2018.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.